ClinicalTrials.gg
CompletedNCT03172780Updated Mar 3, 2022Results posted

A Bioequivalence Study Using Clinical Endpoint for Diclofenac Sodium Gel 1% in Osteoarthritis Knee"

A Phase 3 interventional study of Diclofenac sodium gel 1% and Voltaren® Gel (Diclofenac Sodium Topical Gel) 1% in Osteoarthritis, Knee, sponsored by Mylan Pharmaceuticals Private Limited. Completed at 32 sites in India. Open to participants aged 35 Years and older. Per ClinicalTrials.gov, last updated 2022-03-03.

Sponsored by Mylan Pharmaceuticals Private Limited (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,220
Allocation
Randomized
Ages
35 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Osteoarthritis, Knee with a site in India — 1 open to participants now, 1 under way, none of them phase 3. Osteoarthritis, Knee · India.

Enrollment
2nd of 22
1,220 · median 104
Started
2017
with 3 others
Phase 3
2 of 24
none open now
Registered
7th of 24
by date

Among the 24 studies in Osteoarthritis, Knee with a site in India, this one is the 2nd largest by enrollment of the 22 interventional ones that give a count, is one of 4 that started in 2017, is one of 2 in phase 3, and was the 7th registered.

Osteoarthritis, Knee

3,295 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

1 of the 24 studies in Osteoarthritis, Knee with a site in India is open now. Recruiting first, the newest first:

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 35 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Osteoarthritis, Knee with a site in India, or all of them as a file.
02

Study summary

This randomized, double-blind, three-arm, placebo controlled, bioequivalence study with clinical endpoint has been designed to establish clinical equivalence and safety of Mylan's diclofenac gel in the symptomatic treatment of osteoarthritis of knee compared to Voltaren® gel and to establish superiority in efficacy of both compared to a placebo (vehicle) gel.

Male or non-pregnant female aged ≥ 35 years with a clinical diagnosis of osteoarthritis of the knee according to the American College of Rheumatology (ACR) criteria

Total study duration for the clinical part will be around 56 days that includes screening period of 28 days and treatment period of 4 weeks.

03

Conditions studied

  • Osteoarthritis, Knee
04

Who can participate

Ages eligible
35 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Osteoarthritis knee as per American College of Rheumatology (ACR) criteria
  • Evidence of OA with Kellgren-Lawrence grade 1-3 disease.
  • After discontinuing all pain medications, had at least moderate pain on movement (POM) for target knee
  • After discontinuing all pain medications for at least 7 days has a baseline Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC Likert (version 3.1)) pain subscale of ≥ 9 immediately prior to randomization.
  • Able to tolerate rescue medication with acetaminophen
  • Subjects who can read and understand WOMAC pain sub scale

Exclusion criteria

Exclusion Criteria:

  • Pregnancy, lactation
  • OA of Kellgren-Lawrence grade 4
  • OA pain in the contralateral knee requiring medication (OTC or prescription)
  • History of OA of either Hip or Hands
  • History of secondary OA (e.g. congenital, traumatic, gouty arthritis), rheumatoid arthritis
  • History of chronic inflammatory disease (e.g., colitis) or fibromyalgia
  • History of Drugs or Alcohol abuse within the previous year
  • Symptomatic peripheral vascular disease of the study leg
  • Any musculoskeletal condition
  • Skin disease at the application site
  • Active asthma requiring periodic treatment with systemic
  • Known history of positive , virus, or
  • Uncontrolled hypertension
  • History of myocardial infarction, thrombotic events, stroke etc.
  • Allergy to aspirin, nonsteroidal anti-inflammatory drugs (NSAID) or acetaminophen (paracetamol).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,220 participants (actual)

Study arms

  • Experimental
    Diclofenac Sodium Gel

    Diclofenac Sodium Gel, 1%

    Drug: Diclofenac sodium gel 1%

  • Active comparator
    Voltaren® Gel

    Voltaren® Gel (Diclofenac Sodium Topical Gel) 1%

    Drug: Voltaren® Gel (Diclofenac Sodium Topical Gel) 1%

  • Placebo comparator
    Placebo gel

    Placebo gel

    Drug: Placebo gel

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change in the Total WOMAC Pain Subscale Score

    Mean change in the total WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) pain subscale score for the target knee was compared to determine the clinical equivalence of Test Drug (Diclofenac sodium gel of 1% of Mylan Inc.) with the Reference Listed Drug (RLD) (Voltaren® Gel 1% of Novartis Consumer Health, Inc.) Measure Description: Western Ontario and McMaster Universities Osteoarthritis Index WOMAC pain subscale score (pain score = min 0 to max 20), was determined by the sum of subject's responses to five questions (S1-S5) using a 5-point Likert scale (i.e., 'none'=0; 'mild'=1, 'moderate'=2; 'severe'=3; 'extreme'=4). Higher values represent worse outcome. 'How much pain do you have' when 'Walking on a flat surface' (S1), 'Going up or down stairs' (S2), 'at night while in bed' (S3), 'Sitting or lying' (S4), 'Standing upright' (S5)\]. The timepoints considered for the primary outcomes include baseline and week 4.

    Time frame: From baseline to week 4

  2. Change From Baseline in WOMAC Pain Subscale Score

    Mean change in the total WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) pain subscale score for the target knee was compared to determine the superiority of the Test Drug and Reference Listed Drug (RLD) over placebo. Measure Description: Western Ontario and McMaster Universities Osteoarthritis Index WOMAC pain subscale score (pain score = min 0 to max 20), was determined by the sum of subject's responses to five questions (S1-S5) using a 5-point Likert scale (i.e., 'none'=0; 'mild'=1, 'moderate'=2; 'severe'=3; 'extreme'=4). Higher values represent worse outcome. 'How much pain do you have' when 'Walking on a flat surface' (S1), 'Going up or down stairs' (S2), 'at night while in bed' (S3), 'Sitting or lying' (S4), 'Standing upright' (S5)\]. The timepoints considered for the primary outcomes include baseline and week 4.

    Time frame: 4 weeks

07

Results

Posted Apr 20, 2021

Participant flow

Participant flow — Overall Study
MilestoneDiclofenac Sodium GelVoltaren® GelPlacebo Gel
Started406409405
Completed388389389
Not completed182016

Outcome measures

PrimaryMean Change in the Total WOMAC Pain Subscale Score

Mean change in the total WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) pain subscale score for the target knee was compared to determine the clinical equivalence of Test Drug (Diclofenac sodium gel of 1% of Mylan Inc.) with the Reference Listed Drug (RLD) (Voltaren® Gel 1% of Novartis Consumer Health, Inc.) Measure Description: Western Ontario and McMaster Universities Osteoarthritis Index WOMAC pain subscale score (pain score = min 0 to max 20), was determined by the sum of subject's responses to five questions (S1-S5) using a 5-point Likert scale (i.e., 'none'=0; 'mild'=1, 'moderate'=2; 'severe'=3; 'extreme'=4). Higher values represent worse outcome. 'How much pain do you have' when 'Walking on a flat surface' (S1), 'Going up or down stairs' (S2), 'at night while in bed' (S3), 'Sitting or lying' (S4), 'Standing upright' (S5)\]. The timepoints considered for the primary outcomes include baseline and week 4.

Time frame:
From baseline to week 4
Reported as:
Mean · score on a scale
Mean Change in the Total WOMAC Pain Subscale Score
score on a scaleDiclofenac Sodium GelVoltaren® Gel
Mean Change in the Total WOMAC Pain Subscale Score-4.3 ± 2.64-4.6 ± 2.64
PrimaryChange From Baseline in WOMAC Pain Subscale Score

Mean change in the total WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) pain subscale score for the target knee was compared to determine the superiority of the Test Drug and Reference Listed Drug (RLD) over placebo. Measure Description: Western Ontario and McMaster Universities Osteoarthritis Index WOMAC pain subscale score (pain score = min 0 to max 20), was determined by the sum of subject's responses to five questions (S1-S5) using a 5-point Likert scale (i.e., 'none'=0; 'mild'=1, 'moderate'=2; 'severe'=3; 'extreme'=4). Higher values represent worse outcome. 'How much pain do you have' when 'Walking on a flat surface' (S1), 'Going up or down stairs' (S2), 'at night while in bed' (S3), 'Sitting or lying' (S4), 'Standing upright' (S5)\]. The timepoints considered for the primary outcomes include baseline and week 4.

Time frame:
4 weeks
Reported as:
Mean · score on a scale
Change From Baseline in WOMAC Pain Subscale Score
score on a scaleDiclofenac Sodium GelVoltaren® GelPlacebo Gel
Change From Baseline in WOMAC Pain Subscale Score-4.2 ± 2.84-4.4 ± 2.74-3.2 ± 3.46

Adverse events

Collected over The reporting period for TEAEs started after the informed consent through day 28 after the last application of investigational product, a total of approximately 12 weeks.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Diclofenac Sodium Gel0/398 (0%)0/398 (0%)11/398 (2.8%)
Voltaren® Gel1/405 (0.2%)1/405 (0.2%)19/405 (4.7%)
Placebo Gel0/400 (0%)0/400 (0%)20/400 (5%)
Most frequent serious events
Most frequent serious events
EventDiclofenac Sodium GelVoltaren® GelPlacebo Gel
Completed SuicidePsychiatric disorders0/3981/4050/400
Most frequent other events
Most frequent other events
EventDiclofenac Sodium GelVoltaren® GelPlacebo Gel
HeadacheNervous system disorders4/3989/40511/400
PyrexiaGeneral disorders6/3986/4059/400
EosinophiliaBlood and lymphatic system disorders1/3984/4050/400

Baseline characteristics

Age, Continuous
Age, Continuous(years)Diclofenac Sodium GelVoltaren® GelPlacebo GelTotal
Mean53.3 ± 9.5153.4 ± 9.4053.6 ± 10.1553.4 ± 9.68
Sex: Female, Male
Sex: Female, Male(Participants)Diclofenac Sodium GelVoltaren® GelPlacebo GelTotal
Female275288273836
Male131121132384
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Diclofenac Sodium GelVoltaren® GelPlacebo GelTotal
Asian/Not Hispanic or Latino4064094051220
Region of Enrollment
Region of Enrollment(participants)Diclofenac Sodium GelVoltaren® GelPlacebo GelTotal
India4064094051220
WOMAC Pain subscale score for target knee
WOMAC Pain subscale score for target knee(units on a scale)Diclofenac Sodium GelVoltaren® GelPlacebo GelTotal
Mean12.4 ± 2.1512.5 ± 2.1612.4 ± 2.0512.4 ± 2.12
08

Study locations

32 sites
  • Yashoda Hospital - Malakpet
    Hyderabad, Andhra Pradesh 500036, India
  • Yashoda Hospital -Secunderabad
    Secunderabad, Andhra Pradesh 500003, India
  • Yashoda Hospital -Somajiguda
    Somajiguda, Andhra Pradesh 500082, India
  • King George Hospital
    Visakhapatnam, Andhra Pradesh 530002, India
  • Riddhi Medical Nursing Home
    Ahmedabad, Gujarat 380008, India
  • Rathi Hospital
    Ahmedabad, Gujarat 380015, India
  • Sanjivani Superspeciality Hospital Pvt. Ltd
    Ahmedabad, Gujarat 380015, India
  • B.J Medical College & Civil Hospital
    Ahmedabad, Gujarat 380016, India
  • GMERS Medical College & Civil Hospital
    Ahmedabad, Gujarat 380061, India
  • SSG Hospital and Medical College
    Baroda, Gujarat 39000, India
  • Medistar Multispeciality Hospital
    Himmatnagar, Gujarat 383001, India
  • Shree Giriraj Multispeciality Hospital
    Rajkot, Gujarat 360005, India
  • Anand Multispeciality Hospital
    Vadodara, Gujarat 390016, India
  • Parul Sevashram Hospital
    Vadodara, Gujarat 391760, India
  • Omega Hospital
    Mangalore, Karnataka 575002, India
  • Mysore Medical College and Research Institute
    Mysore, Karnataka 570001, India
  • Sree Narayana Institute of Medical Science
    Ernakulam, Kerala 683594, India
  • Sir J. J. Group of Hospital and Grant Government Hospital
    Mumbai, Maharashtra 400008, India
  • Lokmanya Tilak Municipal Medical College & General Hospital
    Mumbai, Maharashtra 400022, India
  • Government Medical College and Hospital
    Nagpur, Maharashtra 440003, India
  • Jasleen Hospital
    Nagpur, Maharashtra 440012, India
  • Institute of Medical sciences and Lata Mangeshkar
    Nagpur, Maharashtra 600001, India
  • Supe Heart and Diabetes Hospital & Research Centre
    Nashik, Maharashtra 422002, India
  • BJ medical college & Sassoon General Hospital
    Pune, Maharashtra 411001, India
  • Sancheti Institute for Orthopedics & Rehabilitation
    Pune, Maharashtra 411005, India
  • BhaktiVedanta Hospital and Research Institute
    Thane, Maharashtra 401107, India
  • IMS and SUM Hospital
    Bhubaneshwar, Odisha 751003, India
  • Govt Stanley Medical College & Hospital
    Chennai, Tamil Nadu 600001, India
  • M.V. Hospital & Research Centre
    Lucknow, Uttar Pradesh 226003, India
  • Ajanta Research Centre
    Lucknow, Uttar Pradesh 226005, India
  • OM surgical Centre and Maternity Home
    Varanasi, Uttar Pradesh 221007, India
  • Institute of Post Graduate Medical Education and Research (IPGMER), Department of Orthopaedics
    Kolkata, West Bengal 700020, India
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Dec 2017, 6 months.

Results were first posted in Apr 2021, 3 years 4 months after primary completion. A results delay was requested in Jul 2018.

Of 65 industry-sponsored phase 3 interventional studies under Osteoarthritis, Knee, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 27. This study's 6 months is below that.

Counting every sponsor, half of 101 studies reached it within 22 months; a quarter within 15 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2017
First posted
Jun 1, 2017
StartActual
May 24, 2017
Primary completionActual
Dec 5, 2017
CompletionActual
Dec 5, 2017
Results delay requested
Jul 20, 2018
Results first posted
Apr 20, 2021
Last update
Mar 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03172780
Responsible party
Sponsor
First posted
Jun 1, 2017
Start date
May 24, 2017
Primary completion
Dec 5, 2017
Completion
Dec 5, 2017
Results posted
Apr 20, 2021
Last update
Mar 3, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diclofenac Sodium Gel

Start the discussion